ATLASATLAS fair value
ATLAS has no fair value for this stock today.
ORUM (475830.KQ)
ORUM stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · KOSDAQ · South Korea
₩16,070▼ -0.25%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
42%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on ORUM in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On ORUM
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives ORUM a 42% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between ₩12,010 and ₩18,857; in 9 out of 10, between ₩8,051 and ₩28,129. Estimated annual volatility is 138%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩344B
- Market cap (USD)
- $259M
- P/E ratio
- 20.2
- 52-week high
- ₩146,600
- 52-week low
- ₩15,690
- Revenue (12 months)
- ₩40.6M
- Gross margin
- 99.2%
What this means
ATLAS does not publish a fair value for 475830.KQ right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks 475830.KQ has traded between ₩15,690 and ₩146,600. Today it is 89.0% below that high and 2% above its low.
About the company
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States.
Want to see everything about ORUM?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does ORUM do?
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States.
What is the chance 475830.KQ goes up next month?
42%: somewhat worse than a coin flip. In half of the simulated outcomes, 475830.KQ ends the month between ₩12,010 and ₩18,857.
How big is ORUM and what is its P/E ratio?
ORUM's market capitalization is ₩344B. Its price-to-earnings (P/E) ratio is 20.2: you pay ₩20.2 for each ₩1.00 of yearly earnings.
How volatile is 475830.KQ?
ATLAS estimates annual volatility at 138%. In a typical month, half of the outcomes end between ₩12,010 and ₩18,857.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer